PPARA and autoimmune disease: On the other hand, lanifibranor (pan-PPAR agonist) has been examined in a Phase II trial for diffuse cutaneous systemic sclerosis, an autoimmune disease of the connective tissues and has extensive complications in skin, kidneys, heart, lungs, and gastrointestinal tract (NCT02503644).